Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Liver Neoplasms 1Hematologic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 427Magnetic Resonance Spectroscopy 338pembrolizumab 262Biopsy 230Carboplatin 216Cisplatin 180Cyclophosphamide 174Paclitaxel 148Nivolumab 136Gemcitabine 130Radiotherapy 125Dexamethasone 105Bevacizumab 103Radiation 97fludarabine 95Fluorouracil 93Doxorubicin 90Pemetrexed 88Docetaxel 85Rituximab 83durvalumab 82venetoclax 81Oxaliplatin 81Leucovorin 76atezolizumab 70Prednisone 66Lenalidomide 66Capecitabine 66Etoposide 64Vincristine 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cell- and Tissue-Based Therapy × 30 days × Clear all
NCT06084884 2026-05-22

ATHENA

AstraZeneca

Phase 1/2 Active not recruiting
94 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04744116 2026-05-05

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Recruiting
24 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡